Drug profile · INN
ansuvimab-zykl
EBANGA
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
ansuvimab-zykl (EBANGA) is an FDA-listed pharmaceutical active ingredient. Route of administration: iv (infusion). Current US regulatory status: approved.
Key facts
INN ansuvimab-zykl
Brand EBANGA
Route IV (INFUSION)
Formulation POWDER
Frequently asked questions
What is ansuvimab-zykl?
ansuvimab-zykl (EBANGA) is an FDA-listed pharmaceutical active ingredient. Route of administration: iv (infusion). Current US regulatory status: approved.
What is the brand name for ansuvimab-zykl?
EBANGA is a marketed brand name for ansuvimab-zykl. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ansuvimab-zykl?
ansuvimab-zykl has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.